缬沙坦辅助治疗原发性高血压的可行性及安全性

Feasibility and safety of Valsartan in the treatment of essential hypertension

目的探讨缬沙坦辅助治疗原发性高血压的临床治疗效果、对动态血压的改善情况及治疗安全性。方法选取2015年10月~2017年10月我院收治的48例原发性高血压患者,采用随机数字表法将其分为观察组和对照组,每组各24例。观察组给予氨氯地平5 mg/d加缬沙坦80 mg/d,对照组单纯给予氨氯地平5 mg/d,两组均连续治疗5个月,观察比较两组治疗的总有效率、动态血压监测情况以及不良反应发生率。结果观察组的治疗总有效率(95.83%)显著高于对照组的(70.83%),差异有统计学意义(P<0.05)。观察组24 h收缩压(SBP)、24 h收缩压变异性(SBPV)、24 h舒张压(DBP)、24 h舒张压变异性(DBPV)均显著低于对照组,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论缬沙坦辅助治疗原发性高血压临床效果确切,能改善患者的血压状态,且安全性较高,值得临床推广应用。

Objective To investigate the clinical therapeutic effect of Valsartan in the treatment of essential hypertension, the improvement of ambulatory blood pressure and the safety of treatment. Methods Forty-eight patients with primary hypertension admitted to our hospital from October 2015 to October 2017 were selected and divided into observation group and control group according to random number table method, 24 cases in each group. The patients in the observation group were given Ammonia Chloride 5 mg/d plus Valsartan 80 mg/d, the control group received Amlodipine5 mg/d, the two groups were treated for 5 months, the treatment of total effective rate, ambulatory blood pressure monitoring and incidence of adverse reactions were compared detween the two groups. Results The total effective rate of treatment in the observation group(95.83%) was significantly higher than that in the control group(70.83%), and the difference was statistically significant(P<0.05). The 24-hour systolic blood pressure(SBP), 24-hour systolic blood pressure variability(SBPV), 24-hour diastolic blood pressure(DBP), and 24-hour diastolic blood pressure variability(DBPV) were significantly lower in the observation group than in the control group, the differences were statistically significant(P <0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05). Conclusion The clinical effect of valsartan in the treatment of essential hypertension is clear, it can positively improve the blood pressure status of patients, and it is safe and worthy of clinical application.